A recent study demonstrated, in a mouse model in one lab, that bexarotene (FDA-approved for use in non-Hodgkin's lymphoma) is effective against Alzheimer's disease. What should physicians do if patients with Alzheimer's disease begin seeking off-label prescriptions?
No takes yet. Share an insight, caveat, or question.
Lowenthal et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: